Evidence map›Paper›PMID 40697380›Full record

ArticleFrontiers in oncology2025

Case Report: Improved hearing in a rare, adult

Takuya Okada, Manabu Natsumeda, Hidemoto Fujiwara, Nayuta Higa, Toshiaki Akahane, Yuki Watabe, Kaoru Tomikawa, Kyoka Nishita, Yoshihiro Tsukamoto, Shinsuke Ohshima and 6 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Takuya OkadaDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Manabu NatsumedaDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Hidemoto FujiwaraDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Nayuta HigaDepartment of Neurosurgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Toshiaki AkahaneDepartment of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Yuki WatabeDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Kaoru TomikawaDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Kyoka NishitaDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Yoshihiro TsukamotoDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Shinsuke OhshimaDepartment of Otolaryngology, Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Arata HoriiDepartment of Otolaryngology, Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Akihide TanimotoDepartment of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Ryosuke HanayaDepartment of Neurosurgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Hiroshi ShimizuDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.
Akiyoshi KakitaDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.
Makoto OishiDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Brain stem gliomas harboring IDH mutations can be sensitive to temozolomide (TMZ) treatment, unlike their H3K27-altered counterparts, so distinguishing the two is essential. Case presentation: Here, we report an adult brainstem glioma patient whose hearing loss normalized after treatment. He presented with gradual left hearing loss from two years before, and magnetic resonance (MR) images showed a diffuse mass lesion involving the pons to left middle cerebral peduncle, including the vestibular and cochlear nuclei. On MR spectroscopy (MRS), 2-hydroxyglutarate (2HG) was elevated to 3.602 mM, suggesting an IDH-mutant glioma. Subsequently, an open biopsy was performed via the lateral suboccipital approach, and the pathological diagnosis was astrocytoma, IDH-mutant, CNS WHO grade 3. Molecular analysis revealed a non-canonical Discussion: Studies have shown that as high as 31% of adult brainstem gliomas are IDH mutant, with most of these mutations being non-canonical Conclusion: The diagnosis of IDH-mutant brainstem gliomas by MRS and integrated analysis of surgically obtained specimens is essential to determine the proper treatment of these rare cases.

Indexed as

2-hydroxyglutarateadult diffuse intrinsic pontine gliomamagnetic resonance spectroscopynon-canonical IDH mutationtemozolomide sensitivity

Identifiers

PMID40697380
PMCPMC12279812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.